Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184

DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development

Harbour BioMed and Sinopharm establish innovation R&D consortium

CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer

Active Biotech doses first patient in amended tasquinimod myelofibrosis study

Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013

EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer

BeOne Medicines expands US manufacturing with USD300m investment

GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC

Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial

Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia

Lupin spins out two oncology programmes to Kaveri Therapeutics

Fuse Oncology launches new prescribing and treatment-intent solution FuseRx

Tempus agrees to acquire Personalis in USD1.5bn precision oncology deal

Evaxion to present three-year cancer vaccine data at ESMO Congress 2026